SMARCA4 and neoplasm: Chemotherapy, particularly paclitaxel plus carboplatin, is commonly used but has limited efficacy.5 Immune checkpoint inhibitors (ICIs) have shown promise due to the similarity between SMARCA4-UT and SMARCA4-deficient NSCLC.14 However, studies on ICIs have yielded mixed results, and treatment response does not consistently correlate with biomarkers such as PD-L1 expression, tumor mutation burden, or microsatellite stability status.